Amid ice and snow, a blazing flame atop a newly unveiled cauldron marked the opening of the 9th Asian Winter Games in Harbin, Heilongjiang province, on Feb. 7. The torch tower was designed by teachers ...

The NFL’s Super Bowl LIX brand campaign, NFL Flag 50, which is set to debut directly after the Apple Music Halftime Show, is ...

Royalty Pharma (RPRX) expects 2025 Portfolio Receipts to be between $2,900 million and $3,050 million, representing expected growth of 4% to ...

Royalty Receipts grew 12% to $729 million in the fourth quarter and 13% to $2,771 million for full year 2024, driven by strong performance from ...

Pablo Legorreta, CEO, highlighted strong 2024 performance, with Portfolio Receipts reaching $2.8 billion, at the high end of guidance and representing 13% growth in Royalty Receipts. He noted this ...

Outperformance during the fourth quarter primarily resulted from stock selection and an overweight in industrials. Read more ...

Japan's Mitsubishi Chemical said on Friday it will sell pharmaceutical unit Tanabe Mitsubishi Pharma to U.S. private equity firm Bain Capital in a deal worth 510 billion yen ($3.36 billion) as it ...

by adding them to the Chiesi portfolio, we hope to make them available to even more patients who may require them.” Chief executive officer and co-founder of Amryt Pharma, Dr Joe Wiley ...

The transaction, expected to close in the first half of this year, will cost Novartis $925 million upfront with potential ...

So, accumulating at current levels will not make sense. Exit and accept the loss. Mankind Pharma (₹2,518.40): The long-term trend is up. Within that, the stock is in a corrective fall.

It has upgraded the ratings of 24 companies in its pharma portfolio since April 2024, on account of a continued improvement in the business and financial profile, high operating cash flow conversion, ...

Patron Points Inc. a loyalty solutions provider dedicated to the convenience industry announced today it is celebrating the ...